SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock and bond offerings to finance AI and data-center expansion are driving attention, with traders weighing dilution and debt concerns against managements view that the funding is part of a previously outlined investment plan. Bears criticize the timing and financial risk, while bulls see the capital raise as necessary to support growth.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders focused on the fixed share-exchange ratio and the long wait for the deal to close. Many LITE holders object to the terms and worry its value will track Marvells share price, helping explain the selloff despite the announced premium; others see strategic value in combining optics and AI-data-center connectivity businesses.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum is driving discussion, as the deal aims to combine Marvells connectivity chips with Lumentums optical technology for AI data centers. Traders are divided: some see strategic value in expanding Marvells optics business, while others worry about shareholder dilution, the deals cost and long path to completion, contributing to selling pressure.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluences CEO, CFO and chief customer success officer are leaving, with interim leaders appointed and permanent searches underway. Traders are split between viewing the shake-up as a chance to reset management and doubting it will fix the companys manufacturing and execution problems; some also speculate about short-squeeze potential.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsomes Q3 results beat expectations, with strong growth in its commercial portfolio, particularly Auvelity, prompting bullish reactions about the companys path toward cash-flow positivity. The shares decline despite the report has frustrated investors, while others point to rising expenses and the lack of quantified guidance on profitability as reasons for caution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POETs reported presence in Foxconns photonics ecosystem at Tech Day has revived interest in its FIT collaboration and prospects for commercial orders, though traders caution that a demo or product photo does not confirm scaled shipments. The MarvellLumentum deal is also fueling debate: some see it as validation of optical networking demand and a boost to independent suppliers, while others worry about tougher competition and supply-chain control.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios accelerated FDA approval of a competing recurrent respiratory papillomatosis therapy has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rivals dosing regimen will challenge uptake or whether Precigens commercial head start, full approval and payer access will preserve its advantage; quarterly results are also seen as a test of launch momentum.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a fresh 52-week high ahead of the Q3 results and business update is driving attention, with traders pointing to BRIUMVIs commercial growth and the anticipated subcutaneous formulation data. Bullish call activity and high short interest have fueled squeeze and buyout speculation, though some caution that expectations are elevated heading into the results.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus Q3 results beat expectations and the company raised its full-year revenue outlook, with growth in diagnostics and data businesses drawing bullish attention. Traders are debating the weak share-price reaction despite the upbeat report, including whether improved profitability is as strong as it appears after accounting for unrealized investment gains.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is drawing attention after DaVitas preliminary outlook suggested DefenCaths reimbursement could decline through 2027, triggering a sharp selloff and renewed concern about the drugs adoption and revenue potential. Traders are divided: some see the comments and comparative ClearGuard data as a threat to DefenCaths economics, while others argue DaVitas estimate is uncertain and are buying the dip.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
